Use Jakavi as soon as patients are eligible to bring the most benefit to their lives^1–4

Patients with MF face increasingly debilitating symptoms as the disease progresses, with symptoms that negatively affect QoL.^5,6

JAKAVI can change lives in MF by offering patients rapid and durable improvements in MF-related symptoms and splenomegaly, regardless of MF risk status.^7,8

Using JAKAVI early may increase benefits for eligible patients with MF, helping to improve their symptom burden so they can get back to being more like themselves^9,10

An ad-hoc analysis of JUMP^§ showed that low-risk patients achieved slightly greater spleen size reductions vs high-risk patients, suggesting that earlier JAKAVI treatment may lead to greater benefits in patients with myelofibrosis.¹⁰

Proactively monitor all your patients’ MF-related symptoms to treat as early as possible those who can benefit from JAKAVI.^1–4

JUMP was a Phase 3b expanded access trial (N=2233) assessing the efficacy and safety of JAKAVI in patients with intermediate- or high-risk MF (n=1114), intermediate-1-risk MF (n=163) and low-risk MF (n=60). Primary endpoint was assessment of JAKAVI tolerability by the frequency, duration and severity of AEs.^10,11

* Data from a retrospective analysis of 408 patients with MF treated with JAKAVI.⁹
† OR=0.25, 95% CI (0.13–0.47), p<0.001.⁹
‡ A symptom response is defined as a ≥50% reduction in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS).⁹

§ Data from an ad-hoc analysis of the safety and efficacy of JAKAVI in a subset of patients in JUMP with DIPSS low-risk MF (n=60).¹⁰

Abbreviations

AE, adverse event; CI, confidence interval; DIPSS, dynamic international prognostic scoring system; JUMP, JAK Inhibitor Ruxolitinib in Myelofibrosis Patients; MF, myelofibrosis; OR, odds ratio; QoL, quality of life; TSS, Total Symptom Score

References

1. Reilly J, et al. Br J Haematol. 2014;167:418–438.
2. National Institute for Health and Care Excellence. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis [TA386]. 2016. Available at: https://www.nice.org.uk/guidance/ta386. Last accessed April 2020.
3. Scottish Medicines Consortium. Ruxolitinib (as phosphate), 5 mg, 15 mg, & 20 mg tablets (JAKAVI®). SMC No 867/13, 2015. Available at: https://www.scottishmedicines.org.uk/media/2277/ruxolitinib_jakavi_final.... Last accessed April 2020.
4. Mesa R, et al. Blood. 2012;120:Abstract 1727.
5. Mesa R, et al. BMC Cancer. 2016;16:167.
6. Vannucchi A, et al. Haematologica. 2015;100:1139–1145.
7. Novartis Pharmaceuticals UK Ltd. JAKAVI® summary of product characteristics. 
8. Vannuchi A and Harrison C. Blood. 2017;129:693–703. 
9. Palandri F, et al. Oncotarget. 2017;8:79073–79086.
10. Guglielmelli P, et al. EHA 2018, 14–17 June; Stockholm, Sweden. Poster PF623.
11. Al-Ali H, et al. Haematologica. 2016;101:1065–1073.